Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Data on Endometriosis Discussed by Researchers at AbbVie (Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National...

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2017 | 06:05pm CEST

Data on Endometriosis Discussed by Researchers at AbbVie (Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women)

By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Uterine Diseases and Conditions - Endometriosis have been published. According to news reporting originating in North Chicago, Illinois, by NewsRx journalists, research stated, "To estimate the prevalence of diagnosed endometriosis (DE) in women in the United States and assess the associated symptomatic burden. An online, cross-sectional survey of women aged 18-49 years was conducted from August 6, 2012, through November 14, 2012."

The news reporters obtained a quote from the research from AbbVie, "Survey data (weighted by age, race, education, income, geographical distribution, and propensity score) were used to estimate the prevalence and symptomatic burden of DE in women in the United States. Weighted logistic regressions were used to assess differences in symptom burden between women with and without endometriosis. The prevalence of DE was estimated at 6.1% (2,922 of 48,020 women surveyed); 52.7% of women were 18-29 years of age when they were diagnosed with endometriosis. Most (86.2%) women experienced symptoms before diagnosis. More women with (vs. without) DE had menstrual pelvic pain/ cramping (52.7 vs. 45.2%), non-menstrual pelvic pain/cramping (36.7 vs. 14.3%), infertility (11.6 vs. 3.4%), and dyspareunia (29.5 vs. 13.4%). Women with endometriosis were also more likely to report severe symptoms (OR (95% CI) 2.7 (2.3-3.1) for menstrual pelvic pain/cramping, 2.2 (1.7-2.9) for non-menstrual pelvic pain/cramping, and 2.4 (1.8-3.2) for dyspareunia)."

According to the news reporters, the research concluded: "The prevalence of DE among US women is notable, and affected women experience a substantial symptom burden."

For more information on this research see: Prevalence and Symptomatic Burden of Diagnosed Endometriosis in the United States: National Estimates from a Cross-Sectional Survey of 59,411 Women. Gynecologic and Obstetric Investigation, 2017;82(5):453-461. Gynecologic and Obstetric Investigation can be contacted at: Karger, Allschwilerstrasse 10, Ch-4009 Basel, Switzerland. (Karger - www.karger.com/; Gynecologic and Obstetric Investigation - content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223845)

Our news correspondents report that additional information may be obtained by contacting A.M. Soliman, AbbVie Inc, Hlth Econ & Outcomes Res, North Chicago, IL 60064, United States (see also Uterine Diseases and Conditions - Endometriosis).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1159/000452660. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: North Chicago, Illinois, United States, North and Central America, Female Urogenital Diseases and Conditions, Pelvic Pain, Diagnostics and Screening, Female Genital Diseases and Conditions, Physiological Sexual Dysfunction, Uterine Diseases and Conditions, Women's Health, Endometriosis, Dyspareunia, AbbVie.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
10/19 ABBVIE : Researchers from AbbVie Report Findings in Medicinal Chemistry [Are We ..
10/19 ENANTA PHARMACEUTICALS : Announces Data to be Presented on AbbVie's MAVYRET&trad..
10/19 ABBVIE (NYSE : ABBV) Discloses Collaboration With Harpoon Therapeutics To Conduc..
10/18 ABBVIE : and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboratio..
10/18 ABBVIE : to Present at the 2017 Credit Suisse Health Care Conference
10/13 ABBVIE : obtains licence for Turnstone Biologics oncolytic viral immunotherapies
10/13 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET Data to be Presented at..
10/12 ABBVIE : and Turnstone Biologics Announce Global Collaboration on Viral Immunoth..
10/12 ABBVIE : ex-dividend day
10/11 ABBVIE : Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pib..
More news
News from SeekingAlpha
11:46a QUARTERLY REVIEW OF DIVGRO : Q3-2017
11:38a More Wizardry For 2017 -- Magic Formula Large Cap Strategy Update, 2017 YTD
10/19 FDA Approval Of Gilead CAR-T Therapy Will Move The Needle
10/18 Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
10/18 AbbVie teams up with Harpoon Therapeutics in immuno-oncology; shares up 1% pr..
Financials ($)
Sales 2017 27 965 M
EBIT 2017 11 938 M
Net income 2017 7 351 M
Debt 2017 25 677 M
Yield 2017 2,70%
P/E ratio 2017 20,17
P/E ratio 2018 16,40
EV / Sales 2017 6,40x
EV / Sales 2018 5,66x
Capitalization 153 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 92,7 $
Spread / Average Target -3,6%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE53.37%153 193
MERCK KGAA-4.68%14 304
KYOWA HAKKO KIRIN CO LTD24.97%10 266
JAZZ PHARMACEUTICALS PLC28.83%8 652
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD33.70%5 811
CONVATEC GROUP-9.02%5 505